61.95 0.00 (0.00%)
After hours: 4:53PM EDT
|Bid||62.00 x 900|
|Ask||61.97 x 800|
|Day's Range||60.80 - 62.00|
|52 Week Range||31.97 - 62.64|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||4.96|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.10|
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a stock with outstanding fundamental characteristics. When we build an...
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.
SAN DIEGO, June 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that the first subject has been dosed in ELEVATE UC 52, the first of two pivotal trials within the Phase 3 ELEVATE UC registrational program evaluating etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC). ELEVATE UC 52 is a treat-through trial with a 12-week induction period followed by 40 weeks of maintenance.
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
SAN DIEGO, June 13, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019, at 1:30 PM EDT. A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally.
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
If you own shares in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) then it's worth thinking about how it contributes to...
WALTHAM, Mass. , May 21, 2019 /PRNewswire/ -- Corvidia Therapeutics Inc., a clinical stage biotechnology company, today announced the appointment of Dr. Preston Klassen , M.D., M.H.S. to its Board of Directors. ...
- ELEVATE UC Phase 3 global program site initiations - New data for both etrasimod and olorinab SAN DIEGO , May 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that ...
Cannabis Sector Weekly Update: Sell-Off amid Market WeaknessCannabis weekly updateLast week, cannabis ETFs fell for the second consecutive week. The Horizons Marijuana Life Sciences ETF (HMMJ) saw a negative price action of 3.1%, while the ETFMG
Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
A live audio webcast of the UBS and RBC presentations will be posted under the investor relations section of Arena's website at www.arenapharm.com. Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
U.S. stocks bounce back from intraday lows Thursday but the S&P 500 and the Nasdaq finished lower for a fourth session as trade tensions ramped up after U.S. President Donald Trump threatened tariff retaliation on China, which he claims “broke the deal”.
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.
Shares of Arena Pharmaceuticals Inc. declined in Wednesday's extended session after the drug company posted quarterly results that fell short of expectations. Arena reported it swung to a first-quarter profit of $620.1 million, or $12.53 a share, from a loss of $32 million, or 80 cents a share, a year earlier. Revenue jumped to $801.1 million versus $1.8 million. First-quarter revenue was bolstered by $800 million associated with upfront payment from United Therapeutics. Anaysts surveyed by FactSet had forecast earnings of $14 a share and revenue of $802 million. Arena shares were down 2.6% after hours.
- Etrasimod ELEVATE UC Phase 3 Program expected to initiate mid-year targeting significant unmet need in ulcerative colitis - Multiple first- or best-in-class therapeutics, strong leadership team and liquidity ...
Key Cannabis Sector Updates: Price Action and Analyst Ratings(Continued from Prior Part)Cannabis updateLast week, Emerald Health Therapeutics (EMH) closed with losses of 9.4%. The company released its fourth-quarter and full-year 2018 earnings last
Key Cannabis Sector Updates: Price Action and Analyst RatingsCannabis stocksCannabis ETFs traded on a negative note last week. The Horizons Marijuana Life Sciences ETF (HMMJ) fell 1.2%, while the ETFMG Alternate Harvest ETF (MJ) gained 0.33%. The
United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.
SAN DIEGO , May 1, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2019 financial results and provide a corporate update on Wednesday, May 8, 2019 , after ...